<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02151175</url>
  </required_header>
  <id_info>
    <org_study_id>BX001</org_study_id>
    <nct_id>NCT02151175</nct_id>
  </id_info>
  <brief_title>Low-intensity Focused Ultrasound Pulsation (LIFUP) for Treatment of Temporal Lobe Epilepsy</brief_title>
  <official_title>LIFUP for Treatment of Temporal Lobe Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BrainSonix Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gerald J &amp; Dorothy R Friedman NY Foundation For Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BrainSonix Inc.</source>
  <brief_summary>
    <textblock>
      We intend to use focused ultrasound to stimulate or suppress brain activity in patients with
      epilepsy. We hypothesize that focused ultrasound is capable of brain stimulation or
      suppression visible with functional MRI, and will not cause tissue damage.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of histological changes</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Symptom Inventory changes</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory changes</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric changes</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological changes</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure frequency changes</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in BOLD signal</measure>
    <time_frame>Same day</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in epileptiform discharges</measure>
    <time_frame>Same day</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in epileptiform discharge %</measure>
    <time_frame>Same day</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Epilepsy, Temporal Lobe</condition>
  <arm_group>
    <arm_group_label>LIFUP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LIFUP</intervention_name>
    <arm_group_label>LIFUP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with clinical evidence from their diagnostic evaluations of unilateral
             hippocampal dysfunction and epileptogenicity.

          -  Subjects with seizures that have been refractory to treatment with at least three
             currently marketed antiepileptic drugs.

          -  Subjects with epilepsy who would clearly benefit from surgical intervention.

          -  Subjects who have been offered a non-dominant anterior-mesial temporal lobe resection
             as treatment for medication refractory epilepsy.

        Exclusion Criteria:

          -  Subjects with a cognitive or psychiatric disorder that limits the ability to give
             informed consent or are unable to cooperate with the testing.

          -  Subjects with dementia, delirium and psychotic symptoms. - Subjects with ferromagnetic
             materials in the head.

          -  Subjects with severe cardiac disease, increased intracranial pressure, or a TENS unit.

          -  Subjects who exhibit primary generalized seizures or pseudoseizures.

          -  Subjects who have seizures secondary to drugs, alcohol, metabolic illness or
             progressive degenerative disease.

          -  Subjects who have experienced status epilepticus during the 3-week baseline period
             prior to the operation.

          -  Subjects (females) who are pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Korb, PhD</last_name>
      <phone>323-510-7532</phone>
      <email>alexkorb@ucla.edu</email>
    </contact>
    <investigator>
      <last_name>John Stern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <last_update_submitted>January 22, 2016</last_update_submitted>
  <last_update_submitted_qc>January 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsy, Temporal Lobe</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

